French regulatory agency agrees lacutamab TELLOMAK trial can resume recruitment in Sézary syndrome and mycosis fungoides

NEXT STORY
Helix BioPharma Corp. Closes $3.0 Million Private Placement
PREV STORY
Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS® (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Stemline Therapeutics Clears First Cohort of Patients in Ongoing SL-801 Phase 1 Trial

NEW YORK, May 03, 2016 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today ...

author_avatar
NASDAQ Market News

Umecrine Cognition appoints Dr. Bruce Scharschmidt to its board of directors

Dr. Scharschmidt most recently served as Senior Vice President and Chief Medical & Development ...

author_avatar
NASDAQ Market News

Sandoz receives positive CHMP opinion for proposed biosimilar infliximab

Sandoz is seeking approval of biosimilar infliximab for use in all indications of its ...

author_avatar
NASDAQ Market News